Lever Bio announces the extension of its Seed Round to over €9 million. The financing supports the development of immuno-oncology therapies designed to reprogram the tumor microenvironment, enabling preclinical toxicology studies and advancing multiple oncology programs toward clinical development within Lever Bio’s growing pipeline.